Is stem cell therapy for Spinal Muscular Atrophy FDA-approved?
Approved SMA medicines and gene therapy are not approvals of stem-cell therapy for SMA. No clinic may transfer their evidence or regulatory status to an MSC, neural-cell or exosome product.
How stem cells are studied for Spinal Muscular Atrophy
Spinal muscular atrophy (SMA) is a genetic motor-neuron disorder usually linked to insufficient SMN protein. Approved SMN-targeted medicines and gene-replacement approaches address the disease pathway; an unmodified MSC infusion does not correct the SMN defect. Neural-cell support or replacement remains a distinct research hypothesis and must not be presented as equivalent to approved gene-targeted therapy.
Am I a candidate? → · Spinal Muscular Atrophy: full overview → · Spinal Muscular Atrophy cost → · Cost →
Evidence checked against ISSCR, FDA and EMA guidance. See our editorial standards. This is information, not medical advice. Educational information, not medical advice; figures indicative.